This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01088/identifier/chemspider/
n7http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n10http://www.rxlist.com/cgi/generic4/
n18http://linked.opendata.cz/resource/drugbank/dosage/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01088/identifier/wikipedia/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01088/identifier/pharmgkb/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01088/identifier/pubchem-compound/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01088/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01088/identifier/drugbank/
n3http://linked.opendata.cz/ontology/drugbank/
n6http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01088/identifier/national-drug-code-directory/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/atc/
n20http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01088
rdf:type
n3:Drug
n3:description
Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It is used to treat pulmonary arterial hypertension (PAH).
n3:dosage
n18:271B6458-363D-11E5-9242-09173F13E4C5 n18:271B6459-363D-11E5-9242-09173F13E4C5
n3:group
investigational approved
n3:halfLife
20-30 minutes
n3:indication
Used for the treatment of pulmonary arterial hypertension.
owl:sameAs
n9:DB01088 n17:DB01088
dcterms:title
Iloprost
adms:identifier
n12:4947911 n13:46507818 n14:DB01088 n15:66215-302-30 n16:6443959 n23:PA164746843 n24:Iloprost
n3:mechanismOfAction
Iloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) and prostaglandin EP1 receptors. Iloprost constricts the ilium and fundus circular smooth muscle as strongly as prostaglandin E2 (PGE2) itself. Iloprost inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time. All of these properties help to antagonize the pathological changes that take place in the small pulmonary arteries of patients with pulmonary hypertension.
n3:packager
n7:271B6455-363D-11E5-9242-09173F13E4C5 n7:271B6453-363D-11E5-9242-09173F13E4C5 n7:271B6454-363D-11E5-9242-09173F13E4C5
n3:toxicity
Overdoses can lead to hypotension, headache, flushing, nausea, vomiting, and diarrhea.
n3:volumeOfDistribution
* 0.7 to 0.8 L/kg
n3:proteinBinding
60%
foaf:page
n6:iloprost.html n10:ventavis.htm
n3:IUPAC-Name
n4:271B645E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6464-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6463-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6460-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6461-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6462-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B6474-363D-11E5-9242-09173F13E4C5 n4:271B645C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B645A-363D-11E5-9242-09173F13E4C5 n4:271B6475-363D-11E5-9242-09173F13E4C5 n4:271B645D-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B645B-363D-11E5-9242-09173F13E4C5
n20:hasATCCode
n21:B01AC11
n3:H-Bond-Acceptor-Count
n4:271B646A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B646B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B6465-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B6466-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B6468-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B6467-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B6469-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed with bioavailability of 63%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
78919-13-8
n3:clearance
* 20 mL/min/kg [Normal subjects]
n3:containedIn
n19:271B6456-363D-11E5-9242-09173F13E4C5 n19:271B6457-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B6470-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B6472-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B6473-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B646F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B646E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B6471-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B645F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B646C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B646D-363D-11E5-9242-09173F13E4C5